PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech, have ...
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant Nantes, France – June 5, 2024, 7:30am CET – OSE ...
"Osé 2 is smaller, softer, quieter, and more powerful. An engineer's dream," Kim Porter, Director of Engineering BEND, Ore.--(BUSINESS WIRE)--The product notoriously banned from CES is back with ...
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis Lusvertikimab ...
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20 th Congress of ECCO NANTES, France – February 24, 2025, 7:30am CET - OSE ...
Nantes, France – February 22, 2023, 6:00 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the online publication in the peer-reviewed ‘The Journal of Immunology’ ...
NANTES, France - March 26, 2025, 6:15 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and ...
Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) therapy lusvertikimab as the French biotech maps out a financially ...
Close to two years after AbbVie handed over $48 million for the rights to Ose Immunotherapeutics’ inflammation drug, the Big Pharma now wants the French biotech to keep an eye on the asset for a while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback